CCO Independent Conference Coverage

2006 Annual Meeting of the European Association for the Study of the Liver*

April 26-30, 2006 | Vienna, Austria

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Updates in HBV Management

Track 1 of 2

Faculty:
		Yves Benhamou, MD, PhD Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Daniel Shouval, MD

Improving HCV Therapy in 2006

Track 2 of 2

Capsule Summaries

Expert Analysis

Faculty:
		Nezam H. Afdhal, MD, FRCPI Peter Ferenci, MD Stephanos J. Hadziyannis, MD

Expert Highlights

Listen to the experts quickly summarize the key issues in viral liver disease highlighted at the conference!

These audio files are in mp3 format. To listen to the audio, simply click "Download Audio." You must be logged on to the clinicaloptions.com site to listen to or download the mp3 files.

	Yves Benhamou, MD, provides a perspective on improvements in hepatitis B virus therapy and future directions in the field. (6 minutes)		Download Audio
	Stephanos J. Hadziyannis, MD, discusses the principles and practice behind the most important presentations in hepatitis C virus and hepatitis B virus management at EASL. (4 minutes)		Download Audio

CCO Slidesets

Updates in HBV Management

Format: Microsoft PowerPoint (.ppt) | File size: 595 KB

Advances in Viral Hepatitis

Format: Microsoft PowerPoint (.ppt) | File size: 326 KB

CCO Daily News (Not required for CME credit)

May 1, 2006

24 weeks of peginterferon alfa-2a plus ribavirin more effective than 16 weeks in patients with HCV genotype 2 or 3

April 30, 2006

April 29, 2006

April 28, 2006

April 27, 2006

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.